Browse articles from EyeWorld.org related to ocular surface disease. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
For years, ophthalmologists had limited prescription options for patients with ocular surface disease. In the last decade, the number of available options has grown with several receiving approval in 2023. Two experts shared their thoughts and experiences with these new options.
The Scheie Eye Institute residents reviewed “Visual outcome and postoperative complications of cataract surgery in patients with ocular surface disorders” from the Journal of Cataract & Refractive Surgery.
“As we continue to see progress in ocular surface therapeutics, we need to continue to evolve our vocabulary surrounding ocular surface disease. I challenge you to start differentiating your ‘dry eye’ patients as you see them in clinic,” said Cornea Editor Julie Schallhorn, MD. Read her introduction to the Cornea section for more details.
Who are the best patients? What are the outcomes like? What’s in store for the future? Three physicians answered these questions and more as they pertain to platelet-derived ocular surface therapies, giving insights on what they wish ophthalmologists knew about these products.
➤ Positive topline results in Phase 3 clinical trial for allergic conjunctivitis treatment ➤ Phase 1b topline data on investigational dry eye drop ➤ First patients dosed in Phase 1b/2 trial for Wnt agonist antibody ➤ Study: U.S. prevalence of diabetic retinopathy ➤ ASCRS news and events
Ensuring that the ocular surface is optimized is a key step before cataract surgery, but it is also important in the context of glaucoma. Two physicians discussed the importance of addressing the ocular surface and what to do prior to glaucoma surgery and combined cataract/glaucoma procedures.
➤ Investigational gene therapy for choroideremia does not meet study endpoints ➤ Positive safety results in Phase 1/2a clinical trial of investigational drug for wet AMD ➤ Patient enrollment complete for Phase 3 clinical trial of sustained-release travoprost implant ➤ Two companies enter collaboration to develop, commercialize ocular surface disease therapies ➤ ASCRS events
When it comes to premium lenses, patients have high expectations for great outcomes. Three physicians discussed some of the technologies they use preoperatively, intraoperatively, and postoperatively to help achieve excellent outcomes.
Dry eye is the single most common reason that patients come into a practitioner’s office, with a prevalence of around 40% of those seeking ophthalmic care, according to Hank Perry, MD, Ophthalmic Consultants of Long Island, New York. What may not be clear in an office visit is that the patient’s sleep position may be a prime factor in his or her condition.
Meibomian gland dysfunction (MGD) is a common finding among patients who seek eyecare. In many patients, the disease is completely asymptomatic. In others, the severity can range from being a mild annoyance to significantly impacting vision and quality of life.